Zobrazeno 91 - 100
of 173
pro vyhledávání: '"Margaret Macro"'
Autor:
Catherine Sebban, Sylvia Snauwaert, Louise Roulin, Gilles Salles, Anne-Ségolène Cottereau, Armando López-Guillermo, Catherine Thieblemont, Margaret Macro, Marc A. Simon, Laetitia Vercellino, Michel Meignan, Franck Morschhauser, Bernadette Corront, Julie Abraham, Pierre Feugier, Bachra Choufi, Gian Matteo Pica, Josette Briere, Reda Bouabdallah, Olivier Casasnovas, Hugo Gonzalez, Christophe Fruchart, Hervé Tilly, Vincent Ribrag, Olivier Fitoussi, Pascal Godmer, Lucie Oberic, Judith Trotman, Laurence Sahnes, Loïc Chartier, Bertrand Coiffier
Publikováno v:
Blood. 132:4199-4199
Introduction : High total metabolic tumor volume (TMTV) measured on 18F-FDG PET/CT before R-CHOP has been shown to be significantly associated with worse progression-free survival (PFS) and overall survival (OS) in patients with diffuse large B-cell
Autor:
Francesca Gay, Graham Jackson, Laura Rosiñol, Sarah A. Holstein, Philippe Moreau, Stefano Spada, Faith Davies, Juan José Lahuerta, Xavier Leleu, Sara Bringhen, Andrea Evangelista, Cyrille Hulin, Ugo Panzani, David A. Cairns, Francesco Di Raimondo, Margaret Macro, Anna Marina Liberati, Charlotte Pawlyn, Massimo Offidani, Andrew Spencer, Roman Hájek, Evangelos Terpos, Gareth J. Morgan, Joan Bladé, Pieter Sonneveld, Jesús San-Miguel, Philip L. McCarthy, Heinz Ludwig, Mario Boccadoro, Maria-Victoria Mateos, Michel Attal
Publikováno v:
JAMA Oncology, 4(10), 1389-1397. American Medical Association
GREDOS: Repositorio Institucional de la Universidad de Salamanca
Universidad de Salamanca (USAL)
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
GREDOS: Repositorio Institucional de la Universidad de Salamanca
Universidad de Salamanca (USAL)
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
Importance Several trials demonstrated the impact of novel agent-based maintenance in newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating the superiority of one regimen over the other, owing to the lack of direct/i
Publikováno v:
Hématologie. 19:217-222
hma.2013.0789 Auteur(s) : Alexandra Audemard1, Xavier Troussard1, Francoise Galateau-Salle2, Margaret Macro1 macro-m@chu-caen.fr 1 Hematologie clinique, 2 Departement de pathologie, CHU de Caen 14000-Caen, Universite de Caen Basse Normandie, UFR de m
Autor:
Margaret Macro
Publikováno v:
Hématologie. 19:165-174
hma.2013.0795 Auteur(s) : Margaret Macro Si l’autogreffe reste en 2013 le traitement de reference en premiere ligne du myelome du sujet jeune (ou eligible a un traitement intensif), la superiorite d’une double intensification ou de l’allogreffe
Autor:
Kevin W. Song, Laurent Garderet, Hannah Hunter, Heinz Gisslinger, Philippe Rodon, Vanessa Houck, Nicolas Leupin, Jin Lu, Maria Teresa Petrucci, Cristina Goncalves, Ken Romeril, Guang Chen, Isabelle Azais, Meletios A. Dimopoulos, Bruno Royer, Margaret Macro, Annette Ervin-Haynes, Chantal Doyen, Richard Leblanc, Chaim Shustik, Thierry Facon, Ulrich Dührsen, Xavier Leleu, Cyrille Hulin, Shaker Dakhil, Fritz Offner, Andrew R. Belch, Richard Eek, Brigitte Pegourie
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(30)
Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods Patients with untreated symptomatic MM
Autor:
Hervé Avet-Loiseau, Sylvain Choquet, Murielle Roussel, Marie Lorraine Chretien, Annie Brion, Bertrand Arnulf, Lotfi Benboubker, Laurent Garderet, Bruno Royer, Margaret Macro, Mourad Tiab, Carine Chaleteix, Sabine Brechignac, Charles Dauriac, Sylvie Cailleres, Philippe Moreau, Lionel Karlin, Luc-Matthieu Forneker, Marc Wetterwald, Laurent Frenzel, Thierry Facon, Karim Belhadj, Jean Pierre Marolleau, Cyrille Hulin, Stephane Minvielle, Xavier Leleu, Momar Diouf, Jean Gabriel Fuzibet
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (18), pp.2125-2132. ⟨10.1200/JCO.2015.63.1929⟩
Journal of Clinical Oncology, 2016, 34 (18), pp.2125-2132. ⟨10.1200/JCO.2015.63.1929⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (18), pp.2125-2132. ⟨10.1200/JCO.2015.63.1929⟩
Journal of Clinical Oncology, 2016, 34 (18), pp.2125-2132. ⟨10.1200/JCO.2015.63.1929⟩
Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765c21d6459f434c72e5e195b3f42070
https://www.hal.inserm.fr/inserm-01822878/file/jco.2015.63.1929.pdf
https://www.hal.inserm.fr/inserm-01822878/file/jco.2015.63.1929.pdf
Autor:
Jean-Jacques Parienti, Margaret Macro, Khaled Benabed, Emilie Reboursiere, Oumedaly Reman, Stéphane Cheze, Anne-Claire Gac, Gandhi Damaj, Agnès Bazin, Quentin Cabrera, Jean-Baptiste Mear, Sylvain Chantepie, Charles Lancesseur, Hyacinthe Johnson-Ansah
Publikováno v:
Transfusion. 57(2)
BACKGROUND There is increasing evidence that excessive blood transfusion may be associated with impaired survival or cardiovascular events. One way to reduce the number of red blood cells (RBCs) is to transfuse 1 unit (1RBC) instead of 2 units of RBC
Autor:
Mathieu Puyade, Karim Belhadj, Brigitte Kolb, Carla Araujo, Arnaud Jaccard, Michel Attal, Odile Luycx, Thomas Dejoie, Bruno Royer, Laurent Garderet, Sylvie Glaisner, Pascal Lenain, Denis Caillot, Anne-Marie Stoppa, Karim Laribi, Hélène Caillon, Jean-Claude Eisenmann, Hervé Avet-Loiseau, Lucie Planche, Pascal Godmer, Jean-Paul Fermand, Philippe Rodon, Murielle Roussel, Marc Wetterwald, Jean-Valère Malfuson, Gerald Marit, Martine Escoffre, Laetitia Biron, Philippe Moreau, Mamoun Dib, Jean Fontan, Thierry Facon, Driss Chaoui, Brigitte Pegourie, Carine Chaleteix, Borhane Slama, Cyrille Hulin, Mourad Tiab, Sabine Brechignac, Margaret Macro, Olivier Allangba, Véronique Dorvaux
Publikováno v:
Blood. 127(21)
The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantat
Autor:
Sylvain P, Chantepie, Jean-Jacques, Parienti, Véronique, Salaun, Khaled, Benabed, Stéphane, Cheze, Anne-Claire, Gac, Hyacinthe, Johnson-Ansah, Margaret, Macro, Gandhi, Damaj, Jean-Pierre, Vilque, Oumedaly, Reman
Publikováno v:
American journal of hematology. 91(6)
In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was
Autor:
Michael Uppenkamp, Vít Procházka, Catherine Thieblemont, R. Bouabdallah, Wolfgang Hiddemann, Michael Pfreundschuh, M. Andre, Marek Trneny, Michael Hallek, Martin Dreyling, Josée M. Zijlstra, Jan Walewski, Roswitha Forstpointner, Eva Hoster, Stephan Kremers, Christian H. Geisler, Vincent Ribrag, Stephan Stilgenbauer, Gérard Lepeu, Bertrand Coiffier, Laurence Sanhes, Wolfram Klapper, Ursula Vehling-Kaiser, Margaret Macro, P. Feugier, H. Tilly, Michael Unterhalt, P. J. Lugtenburg, Michal Szymczyk, Olivier Hermine, Hanneke C. Kluin-Nelemans, F. Di Raimondo, Lothar Kanz, J.K. Doorduijn
Publikováno v:
New England Journal of Medicine, 367(6), 520-531. Massachussetts Medical Society
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Trneny, M, Geisler, C H, Stilgenbauer, S, Thieblemont, C, Vehling-Kaiser, U, Doorduijn, J K, Coiffier, B, Forstpointner, R, Tilly, H, Kanz, L, Feugier, P, Szymczyk, M, Hallek, M, Kremers, S, Lepeu, G, Sanhes, L, Zijlstra-Baalbergen, J M, Bouabdallah, R, Lugtenburg, P J, Macro, M, Pfreundschuh, M, Prochazka, V, Di Raimondo, F, Ribrag, V, Uppenkamp, M, Andre, M, Klapper, W, Hiddemann, W, Unterhalt, M & Dreyling, M H 2012, ' Treatment of Older Patients with Mantle-Cell Lymphoma ', New England Journal of Medicine, vol. 367, no. 6, pp. 520-531 . https://doi.org/10.1056/NEJMoa1200920
New England Journal of Medicine, 367(6), 520-531. MASSACHUSETTS MEDICAL SOC
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Trneny, M, Geisler, C H, Stilgenbauer, S, Thieblemont, C, Vehling-Kaiser, U, Doorduijn, J K, Coiffier, B, Forstpointner, R, Tilly, H, Kanz, L, Feugier, P, Szymczyk, M, Hallek, M, Kremers, S, Lepeu, G, Sanhes, L, Zijlstra-Baalbergen, J M, Bouabdallah, R, Lugtenburg, P J, Macro, M, Pfreundschuh, M, Prochazka, V, Di Raimondo, F, Ribrag, V, Uppenkamp, M, Andre, M, Klapper, W, Hiddemann, W, Unterhalt, M & Dreyling, M H 2012, ' Treatment of Older Patients with Mantle-Cell Lymphoma ', New England Journal of Medicine, vol. 367, no. 6, pp. 520-531 . https://doi.org/10.1056/NEJMoa1200920
New England Journal of Medicine, 367(6), 520-531. MASSACHUSETTS MEDICAL SOC
BACKGROUNDThe long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regime